Transaction Details

Emcure Pharmaceuticals Limited has completed the acquisition of 663,865 equity shares of Gennova Biopharmaceuticals Limited, representing 12.05% of the total issued and paid-up capital. The acquisition was made from individual shareholders through share transfer agreements executed on July 13, 2026 (reference EPL/CS/SE/0057/2026).

Financial Consideration

The aggregate consideration for the transaction is ₹2,318.7 million (Rupees Two Thousand Three Hundred Eighteen Point Seven Million), payable in cash in one or more tranches on closing.

Completion Date and Share Transfer

The equity shares were credited to Emcure's demat account on July 21, 2026, after completion of requisite procedures.

Ownership Impact

Prior to the acquisition, Emcure held 87.95% shareholding in Gennova. Post-acquisition, Emcure's shareholding increased to 100%, making Gennova a wholly-owned subsidiary.

Target Company Information

Gennova Biopharmaceuticals Limited (CIN: U24231PN2001PLC016253) is involved in research and development, manufacturing and marketing of biotechnology-based products.

Financial Performance:

  • FY 2025-26: Turnover ₹4,917.42 million, PAT ₹54.25 million
  • FY 2024-25: Turnover ₹4,299.46 million
  • FY 2023-24: Turnover ₹4,220.82 million

Capital Structure:

  • Authorized Share Capital: ₹650,000,000 (Rupees Six Hundred Fifty Million)
  • Paid-up Share Capital: ₹55,113,650 (Rupees Fifty-Five Million One Hundred Thirteen Thousand Six Hundred Fifty)

Corporate History

Gennova was incorporated on June 19, 2001 as 'Emcure Dragon Biotech Limited'. The name was changed to 'Emcure Biotech Limited' on October 23, 2001, and subsequently to 'Gennova Biopharmaceuticals Limited' on February 15, 2006.

Related Party Transaction Aspects

The transaction qualifies as a related party transaction since Gennova is currently a subsidiary (87.95% owned) and therefore a related party. Additionally, a promoter and director of Emcure is also a director and member of Gennova, and relatives of such director who are members of Gennova are considered related parties. The company confirms the transaction was undertaken at arm's length.

Regulatory Approvals

No governmental or regulatory approvals were required for this acquisition.

Timeline

The indicative time period for completion was on or before July 31, 2026, with actual completion achieved on July 21, 2026.

Geographic Presence

Gennova operates exclusively in India.